Glycated albumin; clinical usefulness

Clinica Chimica Acta

Volumn 433, Issue , 2014, Pages 96-104

  Koga, Masafumi ^a  

^a Kawanishi City Hospital   (Japan)

Author keywords

Diabetes mellitus; Glycated albumin; Glycemic control indicator; HbA1c

Indexed keywords

FRUCTOSAMINE; GLYCOSYLATED ALBUMIN; HEMOGLOBIN A1C; HEMOGLOBIN F; GLUCOSE BLOOD LEVEL; GLYCOSYLATED SERUM ALBUMIN; SERUM ALBUMIN;

ANEMIA; CHRONIC KIDNEY DISEASE; CHRONIC LIVER DISEASE; CLINICAL PRACTICE; DIABETES MELLITUS; GLYCEMIC CONTROL; HEMOLYTIC ANEMIA; HUMAN; HYPERGLYCEMIA; IRON DEFICIENCY ANEMIA; LIVER CIRRHOSIS; NEONATAL DIABETES MELLITUS; POSTPRANDIAL STATE; PREGNANCY; PRIORITY JOURNAL; RENAL ANEMIA; REVIEW; BLOOD; GLUCOSE BLOOD LEVEL; HEMATOLOGIC DISEASES; METABOLISM;

BLOOD GLUCOSE; FRUCTOSAMINE; HEMATOLOGIC DISEASES; HUMANS; POSTPRANDIAL PERIOD; SERUM ALBUMIN;

EID: 84897898535     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2014.03.001     Document Type: Review

References (96)

1. 1c in diabetes mellitus. N Engl J Med 1976, 295:417-420.
2. The Diabetes Control and Complications Trial Research Group The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993, 329:977-986.
3. U.K.Prospective Diabetes Study (UKPDS) Group Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998, 352:837-853.
4. The International Expert Committee International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes. Diabetes Care 2009, 32:1327-1334.
5. Nathan D.M., Cleary P.A., Backlund J.Y., et al. Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005, 353:2643-2653.
6. Panzer S., Kronik G., Lechner K., Bettelheim P., Neumann E., Dudczak R. Glycosylated hemoglobins (GHb): an index of red cell survival. Blood 1982, 59:1348-1350.
7. Panzer S., Graninger W., Kronik G., Bettelheim P., Lechner K. Glycosylated hemoglobin as a long-term parameter in appraising the severity of hemolytic disease. Klin Wochenschr 1983, 61:839-843.
8. Gram-Hansen P., Mourits-Andersen H.T., Eriksen J.E., Grevy C., Olesen L.L. Glycosylated haemoglobin (HbA1c) as an index of the age of the erythrocyte population in non-diabetic patients. Eur J Haematol 1990, 44:201-203.
9. Koga M., Hashimoto K., Murai J., et al. Usefulness of glycated albumin as an indicator of glycemic control status in patients with hemolytic anemia. Clin Chim Acta 2011, 412:253-257.
10. Tarim Ö., Küçükerdoǧan A., Günay Ü., Eralp Ö., Ercan I. Effects of iron deficiency anemia on hemoglobin A1c in type 1 diabetes mellitus. Pediatr Int 1999, 41:357-362.
11. Coban E., Ozdogan M., Timuragaoglu A. Effect of iron deficiency anemia on the levels of hemoglobin A1c in nondiabetic patients. Acta Haematol 2004, 112:126-128.
12. Koga M., Morita S., Saito H., Mukai M., Kasayama S. Association of erythrocyte indices with glycated haemoglobin in pre-menopausal women. Diabet Med 2007, 24:843-847.
13. Koga M., Murai J., Saito H., Mukai M., Matsumoto S., Kasayama S. Influence of iron metabolism indices on glycated haemoglobin but not glycated albumin levels in premenopausal women. Acta Diabetol 2010, 47(Suppl. 1):65-69.
14. Koga M., Murai J., Saito H., Matsumoto S., Kasayama S. Usefulness of glycated albumin as a glycemic control marker after iron treatment for diabetic patients with iron deficiency anemia. J Jpn Diab Soc 2009, 52:341-345. (in Japanese).
15. Phelps R.L., Honig G.R., Green D., Metzger B.E., Frederiksen M.C., Freinkel N. Biphasic changes in haemoglobin A1c concentrations during normal human pregnancy. Am J Obstet Gynecol 1983, 147:651-653.
16. Worth R., Potter J.M., Drury J., Fraser R.B., Cullen D.R. Glycosylated haemoglobin in normal pregnancy: a longitudinal study with two independent methods. Diabetologia 1985, 28:76-79.
17. Hashimoto K., Noguchi S., Morimoto Y., et al. A1C but not serum glycated albumin is elevated in late pregnancy owing to iron deficiency. Diabetes Care 2008, 31:1945-1948.
18. Hashimoto K., Osugi T., Noguchi S., et al. A1C but not serum glycated albumin is elevated because of iron deficiency in late pregnancy in diabetic women. Diabetes Care 2010, 33:509-511.
19. Shimizu I., Hiramatsu Y., Omori Y., Nakabayashi M. Glycated albumin reflects maternal and perinatal outcome in a multicenter study in Japan. Diabetes Pregnancy 2010, 10:27-31. (in Japanese).
20. 1 in cirrhosis of the liver. Diabetes Res 1989, 11:177-180.
21. Koga M., Kasayama S., Kanehara H., Bando Y. CLD (chronic liver disease)-HbA1c as a novel indicator for estimation of mean plasma glucose in patients with chronic liver disease. Diabetes Res Clin Pract 2008, 81:258-262.
22. Bando Y., Kanehara H., Toya D., Tanaka N., Kasayama S., Koga M. Association of serum glycated albumin to glycated haemoglobin A1c ratio with hepatic function tests in patients with chronic liver disease. Ann Clin Biochem 2009, 46:368-372.
23. Aizawa N., Enomoto H., Imanishi H., et al. Elevation of the glycated albumin to glycated hemoglobin ratio during the progression of hepatitis C virus related liver fibrosis. World J Hepatol 2012, 4:11-17.
24. Bando Y., Kanehara H., Aoki K., et al. The glycated albumin to glycated haemoglobin ratio is increasing along with fibrosis stage in non-alcoholic steatohepatitis. Ann Clin Biochem 2012, 49:387-390.
25. Shima K., Chujo K., Yamada M., Komatsu M., Noma Y., Mizuguchi T. Lower value of glycated haemoglobin relative to glycaemic control in diabetic patients with end-stage renal disease not on haemodialysis. Ann Clin Biochem 2012, 49:68-74.
26. Inaba M., Okuno S., Kumeda Y., et al. Glycated albumin is a better glycemic indicator than glycated hemoglobin values in hemodialysis patients with diabetes: effect of anemia and erythropoietin injection. J Am Soc Nephrol 2007, 18:896-903.
27. Peacock T.P., Shihabi Z.K., Bleyer A.J., et al. Comparison of glycated albumin and hemoglobin A1c levels in diabetic subjects on hemodialysis. Kidney Int 2008, 73:1062-1068.
28. Freedman B.I., Andries L., Shihabi Z.K., et al. Glycated albumin and risk of death and hospitalizations in diabetic dialysis patients. Clin J Am Soc Nephrol 2011, 6:1635-1643.
29. Bry L., Chen P.C., Sacks D.B. Effects of hemoglobin variants and chemically modified derivatives on assays for glycohemoglobin. Clin Chem 2001, 47:153-163.
30. Lin C.N., Emery T.J., Little R.R., et al. Effects of hemoglobin C, D, E, and S traits on measurements of HbA1c by six methods. Clin Chim Acta 2012, 413:819-821.
31. Little R.R., Rohlfing C.L., Hanson S.E., et al. The effect of increased fetal hemoglobin on 7 common Hb A1c assay methods. Clin Chem 2012, 58:945-947.
32. Miyashita T., Sugiyama T., Yamadate S., Nagashima M., Satomura A., Nakayama T. Study of a newly developed HPLC analyzer for HbA1c measurements in blood containing hemoglobin variants. Ann Clin Biochem 2014, 10.1177/0004563213513244.
33. Miyazaki A., Kohzuma T., Kasayama S., Koga M. Classification of variant forms of hemoglobin according to the ratio of HbA1c to glycated albumin. Ann Clin Biochem 2012, 49:441-444.
34. Ijima H., Jinnouchi H., Hamaguchi K., et al. Cases with Hb Toranomon show abnormal HbA1c levels measured by upgraded high-performance liquid chromatography models. Diabetol Int 2001, 2:202-207.
35. Nishihara E., Koga M., Kadowaki S., et al. Method-dependent HbA1c values in a family with hemoglobin Himeji. Clin Chim Acta 2011, 412:1689-1692.
36. Nakanishi T., Miyazaki A., Kishikawa M., Shimizu A., Aoki Y., Kikuchi M. Hb Peterborough [beta 111(G13)Val→Phe] in Japan; rapid identification by ESI/MS using proteolytic digests of oxidized globin. Hemoglobin 1998, 22:23-35.
37. Wajcman H., Promé D., Préhu C., et al. Hb Les Andelys [alpha83(F4)LEU→PRO]: a new moderately unstable variant. Hemoglobin 1998, 22:129-140.
38. Moo-Penn W.F., Bechtel K.C., Schmidt R.M., et al. Hemoglobin Raleigh (beta1 valine replaced by acetylalanine). Structural and functional characterization. Biochemistry 1977, 16:4872-4879.
39. Ohba Y., Hattori Y., Sakata S., et al. Hb Niigata [beta 1 (NA1) Val→Leu]: the fifth variant with retention of the initiator methionine and partial acetylation. Hemoglobin 1997, 21:179-186.
40. Suzuki S., Koga M., Niizeki N., et al. Evaluation of glycated hemoglobin and fetal hemoglobin-adjusted HbA1c measurements in infants. Pediatr Diabetes 2013, 14:267-272.
41. 1c reflects glycaemic control in patients with neonatal diabetes mellitus. Diabetologia 2011, 54:2247-2253.
42. Suzuki S., Koga M., Niizeki N., et al. Glycated albumin is lower in infants than in adults and correlated with both age and serum albumin. Pediatr Diabetes 2013, 14:25-30.
43. Suzuki S., Koga M., Niizeki N., Furuya A., Matsuo K., Tanahashi Y., Azuma H. Age-adjusted glycated albumin is a useful indicator for glycemic control in patients with neonatal diabetes mellitus. Ann Clin Biochem 2013, 10.1177/0004563213512617.
44. Bhat V.S., Dewan K.K., Krishnaswamy P.R. Diagnostic dilemma of HbA1c detection in presence of a hemoglobinopathy: a case report. Indian J Clin Biochem 2011, 26:91-95.
45. Takahashi S., Uchino H., Shimizu T., et al. Comparison of glycated albumin (GA) and glycated hemoglobin (HbA1c) in type 2 diabetic patients: usefulness of GA for evaluation of short-term changes in glycemic control. Endocr J 2007, 54:139-144.
46. Koga M., Murai J., Saito H., Kasayama S. Prediction of near-future glycated hemoglobin levels using glycated albumin levels before and after treatment for diabetes. J Diabet Invest 2011, 2:304-309.
47. Hamaguchi T., Koga M., Murai J., et al. Estimation of HbA1c response to sitagliptin by change in glycated albumin level for two weeks. J Diabet Invest 2012, 3:175-178.
48. Koga M., Murai J., Saito H., Kasayama S. Prediction of near-future HbA1c levels using glycated albumin levels before and after glimepiride administration for two weeks is useful to decide the effectiveness of the treatment. Diabetol Int 2012, 3:197-201.
49. Koga M., Suzuki S., Matsuo K., Tanahashi Y., Azuma H., Kasayama S. Calculation of HbA1c and glycated albumin from serially measured self-monitored blood glucose in patients with type 1 diabetes mellitus. Clin Chim Acta 2013, 425:188-191.
50. 1c in the Diabetes Control and Complications Trial. Diabetes Care 2002, 25:275-278.
51. Hirata T., Saisho Y., Morimoto J., Kasayama S., Koga M., Maruyama T. The ratio of glycated albumin to HbA1c is correlated with diabetes duration according to decreases in insulin secretion in patients with autoimmune type 1 diabetes and type 2 diabetes. J Genet Syndr Gene Ther 2013, 4:168.
52. Murai J., Soga S., Saito H., Koga M. Usefulness of glycated albumin for early detection of deterioration of glycemic control state after discharge from educational admission. Endocr J 2013, 69:409-413.
53. Imagawa A., Hanafusa T., Miyagawa J., Matsuzawa Y. A novel subtype of type 1 diabetes mellitus characterized by a rapid onset and an absence of diabetes-related antibodies. N Engl J Med 2000, 342:301-307.
54. Koga M., Murai J., Saito H., et al. Serum glycated albumin to hemoglobin A1C ratio is a suitable index for diagnosis of fulminant type 1 diabetes mellitus. Ann Clin Biochem 2010, 47:313-317.
55. Koga M., Murai J., Saito H., et al. Glycated albumin levels are higher relative to HbA1c levels in people with autoimmune acute-onset type 1 diabetes mellitus than in people with type 2 diabetes mellitus at the time of diagnosis. Diabetes Res Clin Pract 2011, 94:e12-e14.
56. The DECODE study group Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. Lancet 1999, 354:617-621.
57. Tominaga M., Eguchi H., et al. Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata Diabetes Study. Diabetes Care 1999, 22:920-924.
58. Chiasson J.L., Josse R.G., Gomis R., Hanefeld M., Karasik A., Laakso M. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 2002, 359:2072-2077.
59. Hanefeld M., Cagatay M., Petrowitsch T., et al. Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies. Eur Heart J 2004, 25:10-16.
60. Sakuma N., Omura M., Oda E., Saito T. Converse contributions of fasting and postprandial glucose to HbA1c and glycated albumin. Diabetol Int 2011, 2:162-171.
61. Yoshiuchi K., Matsuhisa M., Katakami N., et al. Glycated albumin is a better indicator for glucose excursion than glycated hemoglobin in type 1 and type 2 diabetes. Endocr J 2008, 55:503-507.
62. Koga M., Murai J., Saito H., Kasayama S. Glycated albumin and glycated hemoglobin are differently influenced by endogenous insulin secretion in patients with type 2 diabetes mellitus. Diabetes Care 2010, 33:270-272.
63. Saisho Y., Tanaka K., Abe T., Shimada A., Kawai T., Itoh H. Glycated albumin to glycated hemoglobin ratio reflects postprandial glucose excursion and relates to beta cell function in both type 1 and type 2 diabetes. Diabetol Int 2011, 2:146-153.
64. Ogawa A., Hayashi A., Kishihara E., Yoshino S., Takeuchi A., Shichiri M. New indices for predicting glycaemic variability. PLoS One 2012, 7:e46517.
65. Kim D., Kim K.J., Huh J.H., et al. The ratio of glycated albumin to glycated haemoglobin correlates with insulin secretory function. Clin Endocrinol (Oxf) 2012, 77:679-683.
66. Tsutsumi C., Imagawa A., Onishi M. et al. Glycated albumin as a useful clinical biomarker for glycemic variability in type 1 diabetes assessed by continuous glucose monitoring. Diabetol Int 2013, 4:156-159.
67. Suwa T., Ohta A., Matsui T., et al. Relationship between clinical markers of glycemia and glucose excursion evaluated by continuous glucose monitoring (CGM). Endocr J 2010, 57:135-140.
68. Koga M., Murai J., Saito H., Mukai M., Matsumoto S., Kasayama S. Glycated albumin levels are higher relative to glycated haemoglobin levels in gastrectomized subjects. Ann Clin Biochem 2010, 47:39-43.
69. Shiraiwa T., Kaneto H., Miyatsuka T., et al. Postprandial hyperglycemia is a better predictor of the progression of diabetic retinopathy than HbA1c in Japanese type 2 diabetic patients. Diabetes Care 2005, 28:2806-2807.
70. Morita S., Kasayama S., Deguchi R., et al. Glycated albumin, rather than HbA1c, reflects diabetic retinopathy independent of diabetic duration in patients with type 2 diabetes mellitus. J Diabet Metab 2013, 4:278.
71. Pu L.J., Lu L., Shen W.F., et al. Increased serum glycated albumin level is associated with the presence and severity of coronary artery disease in type 2 diabetic patients. Circ J 2007, 71:1067-1073.
72. Song S.O., Kim K.J., Lee B.W., Kang E.S., Cha B.S., Lee H.C. Serum glycated albumin predicts the progression of carotid arterial atherosclerosis. Atherosclerosis 2012, 225:450-455.
73. Kilpatrick E.S., Rigby A.S., Atkin S.L. A1C variability and the risk of microvascular complications in type 1 diabetes: data from the Diabetes Control and Complications Trial. Diabetes Care 2008, 31:2198-2202.
74. Wadén J., Forsblom C., Thorn L.M., Gordin D., Saraheimo M., Groop P.H. Finnish Diabetic Nephropathy Study Group. A1C variability predicts incident cardiovascular events, microalbuminuria, and overt diabetic nephropathy in patients with type 1 diabetes. Diabetes 2009, 58:2649-2655.
75. Bouchi R., Babazono T., Mugishima M., et al. Fluctuations in HbA1c are associated with a higher incidence of cardiovascular disease in Japanese patients with type 2 diabetes. J Diabet Invest 2012, 3:148-155.
76. Koga M., Murai J., Morita S., Saito H., Kasayama S. Comparison of annual variability in HbA1c and glycated albumin in patients with type 1 vs. type 2 diabetes mellitus. J Diabet Complications 2013, 27:211-213.
77. Koga M., Murai J., Saito H., Otsuki M., Kasayama S. Evaluation of the glycated albumin/HbA1c ratio by stage of diabetic nephropathy. Diabetol Int 2011, 2:141-145.
78. Okada T., Nakao T., Matsumoto H., et al. Influence of proteinuria on glycated albumin values in diabetic patients with chronic kidney disease. Intern Med 2011, 50:23-29.
79. Koga M., Murai J., Saito H., Matsumoto S., Kasayama S. Effect of thyroid hormone on serum glycated albumin levels: study on non-diabetic subjects. Diabetes Res Clin Pract 2009, 84:163-167.
80. Kitamura T., Otsuki M., Tamada D., et al. Glycated albumin is set lower in relation to plasma glucose levels in patients with Cushing's syndrome. Clin Chim Acta 2013, 424:164-167.
81. Suzuki S., Koga M., Takahashi H., Matsuo K., Tanahashi Y., Azuma H. Glycated albumin in patients with neonatal diabetes mellitus is apparently low in relation to glycemia compared with that in patients with type 1 diabetes mellitus. Horm Res Paediatr 2012, 77:273-276.
82. Nishimura R., Kanda A., Sano H., et al. Glycated albumin is low in obese, non-diabetic children. Diabetes Res Clin Pract 2006, 71:334-338.
83. Koga M., Matsumoto M., Saito H., Kasayama S. Body mass index negatively influences glycated albumin, but not glycated hemoglobin, in diabetic patients. Endocr J 2006, 53:387-391.
84. Koga M., Otsuki M., Matsumoto S., Saito H., Mukai M., Kasayama S. Negative association of obesity and its related chronic inflammation with serum glycated albumin but not glycated hemoglobin levels. Clin Chim Acta 2007, 378:48-52.
85. Bulló M., Garcia-Lorda P., Megias I., Salas-Salvadó J. Systemic inflammation, adipose tissue tumor necrosis factor, and leptin expression. Obes Res 2003, 11:525-531.
86. Don B.R., Kaysen G. Serum albumin: relationship to inflammation and nutrition. Semin Dial 2004, 17:432-437.
87. Koga M., Saito H., Mukai M., Otsuki M., Kasayama S. Serum glycated albumin levels are influenced by smoking status, independent of plasma glucose levels. Acta Diabetol 2009, 46:141-144.
88. Koga M., Murai J., Saito H., Mukai M., Kasayama S. Serum glycated albumin, but not glycated hemoglobin, is low in relation to glycemia in hyperuricemic men. Acta Diabetol 2010, 47:173-177.
89. Koga M., Murai J., Saito H., Mukai M., Kasayama S. Serum glycated albumin, but not glycated hemoglobin, is low in relation to glycemia in men with hypertriglyceridemia. J Diabet Invest 2010, 1:202-207.
90. Koga M., Murai J., Saito H., Mukai M., Kasayama S. Serum glycated albumin levels, but not glycated hemoglobin, is low in relation to glycemia in non-diabetic men with nonalcoholic fatty liver disease with high alanine aminotransferase levels. Clin Biochem 2010, 43:1023-1025.
91. Armbruster D.A. Fructosamine: structure, analysis, and clinical usefulness. Clin Chem 1987, 33:2153-2163.
92. Ford H.C., Lim W.C., Crooke M.J. Hemoglobin A1 and serum fructosamine levels in hyperthyroidism. Clin Chim Acta 1987, 166:317-321.
93. Sako Y., Umeda F., Hashimoto T., Haji M., Nawata H. Serum fructosamine in assessment of diabetic control and relation to thyroid function. Horm Metab Res 1989, 21:669-672.
94. Constanti C., Simo J.M., Joven J., Camps J. Serum fructosamine concentration in patients with nephrotic syndrome and with cirrhosis of the liver: the influence of hypoalbuminaemia and hypergammaglobulinaemia. Ann Clin Biochem 1992, 29:437-442.
95. Montagna M.P., Laghi F., Cremona G., Zuppi C., Barbaresi G., Castellana M.L. Influence of serum proteins on fructosamine concentration in multiple myeloma. Clin Chim Acta 1991, 204:123-130.
96. Abe F., Yano M., Minami Y., et al. Alterations in fructosamine and glycated albumin levels during childhood. Ann Clin Biochem 1989, 26:328-331.